Rani Therapeutics (RANI) Projected to Post Earnings on Wednesday

Key Points

• Rani Therapeutics is set to report Q1 2026 results before the market opens on May 13, with analysts expecting EPS of ($0.06) and revenue of about $1.125M; an earnings call is scheduled for May 14 at 4:00 PM ET.
• The company recently missed estimates — reporting EPS of ($0.07) and revenue of $1.46M in its last quarter versus consensus of ($0.03) and $5.0M — and analysts now forecast roughly $0 EPS for the current and next fiscal year on average.
• RANI trades around $0.88 with a market cap of about $109M, and analyst sentiment is mixed-to-positive (average rating "Moderate Buy" with an average target of $7.80 amid price targets ranging roughly $5–$11); institutional ownership is ~30%.

Rani Therapeutics (NASDAQ:RANI - Get Free Report) is projected to release its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect Rani Therapeutics to post earnings of ($0.06) per share and revenue of $1.1250 million for the quarter. Interested persons can check the company's upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.

Rani Therapeutics (NASDAQ:RANI - Get Free Report) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.04). The firm had revenue of $1.46 million for the quarter, compared to the consensus estimate of $5.00 million. On average, analysts expect Rani Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Rani Therapeutics Stock Performance

NASDAQ:RANI opened at $0.88 on Wednesday. The firm's 50-day moving average is $1.06 and its 200-day moving average is $1.38. Rani Therapeutics has a 52-week low of $0.39 and a 52-week high of $3.87. The company has a market cap of $109.33 million, a price-to-earnings ratio of -1.50 and a beta of 0.74.

Analysts Set New Price Targets

Several research firms have recently issued reports on RANI. HC Wainwright restated a "buy" rating and set a $11.00 price objective on shares of Rani Therapeutics in a report on Friday, March 27th. Lake Street Capital began coverage on shares of Rani Therapeutics in a report on Tuesday, April 14th. They set a "buy" rating and a $9.00 price objective on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Rani Therapeutics in a report on Friday, March 27th. Finally, Canaccord Genuity Group dropped their price objective on shares of Rani Therapeutics from $9.00 to $5.00 and set a "buy" rating on the stock in a report on Wednesday, April 1st. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $7.80.

Hedge Funds Weigh In On Rani Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in RANI. RA Capital Management L.P. bought a new position in shares of Rani Therapeutics during the 4th quarter worth about $11,475,000. AWM Investment Company Inc. bought a new position in shares of Rani Therapeutics during the 4th quarter worth about $8,775,000. SymBiosis Capital Partners LLC bought a new position in shares of Rani Therapeutics during the 4th quarter worth about $8,505,000. Armistice Capital LLC bought a new position in shares of Rani Therapeutics during the 2nd quarter worth about $1,619,000. Finally, Siren L.L.C. bought a new position in shares of Rani Therapeutics during the 4th quarter worth about $2,700,000. 30.19% of the stock is owned by institutional investors.

About Rani Therapeutics

Rani Therapeutics is a clinical-stage biopharmaceutical company developing oral delivery technologies for large-molecule drugs. The company's proprietary RaniPill platform is designed to enable the gastrointestinal delivery of biologic therapies traditionally administered via injection. Through a swallowable capsule that autonomously deploys a microscopic injector in the small intestine, Rani aims to improve patient convenience and adherence for peptide and protein therapies, including insulin and other hormones.

Since its founding in 2012, Rani Therapeutics has advanced its lead programs through early-phase clinical trials, demonstrating proof-of-concept for oral insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.